Headlines

$200M Expansion of Eyecare Drug Plant Called Off

The factory produces Restasis.

Published

5 years ago

November 14, 2018

Allergan has called off plans for a $200 million expansion of its pharmaceutical plant in Waco, TX, which produces eyecare drugs.

Plans announced in 2016 had called for adding 322,000 square feet and 250 jobs, the Waco Tribune reports. Local governments were ready to provide incentives worth $4 million.

Allergan produces Restasis, a treatment for dry eye, in Waco. FiercePharma reports: “Because of a court ruling last year striking down its patents, the company expects to face generic competition soon, perhaps this year.”

Allergan told media outlets in a statement: “As part of Allergan’s commitment to operational excellence, we are focused on improving efficiencies at our global manufacturing sites, including Waco. This commitment, coupled with the expected loss of exclusivity for Restasis in 2018, has shifted our priority from expanding the Waco site to investing significantly in our existing operations.”

The Waco Tribune also quoted a spokeswoman saying the company “remains committed to our eye care business and operations in Waco.”

Read more at the Waco Tribune

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.